Capricor Therapeutics, Inc.
CAPR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001133869
No open-market purchases or sales by Capricor Therapeutics, Inc. insiders were filed in the last 90 days; 169 institutions reported holding it in 13F filings for Q2 2026, worth $941.6M in total; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding Capricor Therapeutics, Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Q2 2022 | Change |
|---|---|---|---|
| Holders | 29 | 29 | 0 |
| Shares | 2.59M | 2.54M | −48.0K (−1.9%) |
| Value | $8.88M | $8.87M | −$8.68K (−0.1%) |
New holders (4)
Institutions that held Capricor Therapeutics, Inc. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Bailard, Inc. | 29,801 | $104.0K | 0.00% |
| Bank of America Corp | 5,000 | $17.0K | 0.00% |
| Tower Research Capital LLC (TRC) | 1,684 | $5.00K | 0.00% |
| New Millennium Group LLC | 69 | $0 | 0.00% |
Sold out (4)
Institutions that held Capricor Therapeutics, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Selective Wealth Management, Inc. | 213,494 | $732.0K |
| Captrust Financial Advisors | 1,190 | $4.00K |
| Citigroup Inc | 20 | $0 |
| Ancora Advisors, LLC | 1,786 | – |